A carregar...
Are We Ready to Use ESR1 Mutations in Clinical Practice?
The recurrent ligand-binding domain ESR1 mutations are an important mechanism of endocrine resistance in estrogen receptor-positive (ER+) metastatic breast cancer. These mutations evolve under the selective pressure of endocrine treatments and are rarely found in treatment-naïve ER+ breast cancers....
Na minha lista:
| Publicado no: | Breast Care (Basel) |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
S. Karger GmbH
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5704725/ https://ncbi.nlm.nih.gov/pubmed/29234250 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000481428 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|